NCT04297748View on ClinicalTrials.gov

Bioimaging Study of 89Zr-M7824 in NSCLC

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Non-Small Cell Lung Cancer
Interventions
COMBINATION_PRODUCT

89Zirconium-M7824

PET imaging agent

DRUG

M7824

Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.

Trial Locations (1)

3078

Austin Health, Heidelberg

Sponsors

Collaborators (1)

Austin Health
All Listed Sponsors
collaborator

Merck Healthcare KGaA

UNKNOWN

collaborator

Austin Health

OTHER_GOV

lead

Olivia Newton-John Cancer Research Institute

OTHER

NCT04297748 - Bioimaging Study of 89Zr-M7824 in NSCLC | Biotech Hunter | Biotech Hunter